| Sandoz Pharmaceuticals AG - Ruxolitinib Sandoz 15 mg, Tabletten |
| 70733 | | 03 | | Ruxolitinib Sandoz 15 mg | | Tabletten | | L01EJ01 | | Ruxolitinib | | 04.05.2026 | | |
|
| Composition |
| ruxolitinibum 15 mg ut ruxolitinibi hydrochloridum, lactosum monohydricum 225.015 mg, cellulosum microcristallinum, povidonum K 29-32, hydroxypropylcellulosum, carboxymethylamylum natricum A, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium max. 1.29 mg. |
| Packungsbestandteile |
| Comprimés | | | | Principe actif | Concentr. |
|---|
| Ruxolitinibum | 15 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Carboxymethylamylum Natricum A | | | Cellulosum Microcristallinum | | | Hydroxypropylcellulosum | | | Lactose Monohydrate | 225.015 mg | | Magnesii Stearas | | | Povidonum K | 29-32 | | Pro Compresso | | | Silica Colloidalis Anhydrica | |
|
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 005 | 56 | | | A | | Oui | | 006 | 168 | | | A | | Oui |
|
